AcoArt IV / SFA in China:Drug-eluting Balloon for SFA Angioplasty Evaluation in China
Launched by ACOTEC SCIENTIFIC CO., LTD · Aug 28, 2017
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
PTA is an established alternative to open surgical bypass for the treatment of infrainginual disease of critical limb ischemia.
DEBs are designed to promote arterial patency by reducing neointimal proliferation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 18 and 80 years
- • Patients with peripheral artery disease (PAD), with Rutherford classification between 2 and 5
- • an occlusion or a minimum grade of stenosisPrimary over 70% in the superficial femoral artery an /or the popliteal artery
- • Total length of treat lesion(s)is less or equal to 20cm
- • signed Patient informed consent form
- Exclusion Criteria:
- • plasma Cr level greater than 150 umol/L in patients
- • patients with acute thrombosis requiring lysis or thrombectomy
- • 2 or more than 2 stenosis lesions in traget vessel
- • patient with a lysis or an lower limb intervention as a therapy within the last 6 weeks
- • patient requiring intervention in both lower limbs at the same time
- • have \>30% residual stenosis or blood-limited dissection after predilation
- • distal outflow through less than one lower leg vessel
- • known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium, etc.
- • patients participating in another clinical trials with interfere with this trial in the past 3 months
- • pregnancy and lactating woman
- • untreatable bleeding diatheses
- • other diseases, such as cancer, liver disease, or cardiac insufficiency, which may lead to protocol violations or markedly shorten a patients's life expectancy(less than 1 years)
- • patients unable or unwilling to participate this trial
About Acotec Scientific Co., Ltd
Acotec Scientific Co., Ltd. is a leading biotechnology company dedicated to advancing healthcare through innovative diagnostic and therapeutic solutions. With a strong focus on research and development, Acotec specializes in the development of cutting-edge medical devices and pharmaceuticals that enhance patient outcomes and streamline clinical workflows. The company is committed to rigorous clinical trials and regulatory compliance, ensuring the safety and efficacy of its products. Acotec's mission is to leverage science and technology to address unmet medical needs and contribute to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shijiazhuang, Hebei, China
Nanjing, Jiangsu, China
Beijing, Beijing, China
Tianjin, Tianjin, China
Shenyang, Liaoning, China
Beijing, Beijing, China
Harbin, Heilongjiang, China
Dalian, Liaoning, China
Wuhan, Hubei, China
Nanjing, Zhejiang, China
Patients applied
Trial Officials
Wei Guo
Principal Investigator
Chinese PLA General Hospital
Yinghua Zou
Principal Investigator
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials